Michael S. Gordon

机构：HonorHealth, Friends Research Institute · ORCID：0000-0002-7679-9504

发表论文 569 篇 · 总被引 28485 次 · h-index 74

代表论文

• Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial (2024 · Nature Medicine · 被引 134)
• A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer (2025 · ESMO Open · 被引 75)
• Physical, biochemical, and biological characterization of olive-derived lipid nanovesicles for drug delivery applications (2024 · Journal of Nanobiotechnology · 被引 25)
• Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas (2025 · Journal of Clinical Oncology · 被引 23)
• Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer (2025 · Journal for ImmunoTherapy of Cancer · 被引 14)
• 1690O NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study (2024 · Annals of Oncology · 被引 11)